Z

Zenas Biopharma Inc
NASDAQ:ZBIO

Watchlist Manager
Zenas Biopharma Inc
NASDAQ:ZBIO
Watchlist
Price: 36.89 USD 13.19% Market Closed
Market Cap: 2B USD

Wall Street
Price Targets

ZBIO Price Targets Summary
Zenas Biopharma Inc

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZBIO is 45.9 USD with a low forecast of 36.36 USD and a high forecast of 57.75 USD.

Lowest
Price Target
36.36 USD
1% Downside
Average
Price Target
45.9 USD
24% Upside
Highest
Price Target
57.75 USD
57% Upside
Zenas Biopharma Inc Competitors:
Price Targets
CRSP
CRISPR Therapeutics AG
43% Upside
006280
Green Cross Corp
17% Upside
ASND
Ascendis Pharma A/S
26% Upside
SBTX
SkinBioTherapeutics PLC
117% Upside
688278
Xiamen Amoytop Biotech Co Ltd
21% Upside
SKYE
Skye Bioscience Inc
647% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
34% Upside
ANAB
AnaptysBio Inc
36% Upside

Revenue
Forecast

Revenue Estimate
Zenas Biopharma Inc

For the last 1 year the compound annual growth rate for Zenas Biopharma Inc's revenue is -90%. The projected CAGR for the next 4 years is 130%.

-90%
Past Growth
130%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Zenas Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Zenas Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZBIO's stock price target?
Price Target
45.9 USD

According to Wall Street analysts, the average 1-year price target for ZBIO is 45.9 USD with a low forecast of 36.36 USD and a high forecast of 57.75 USD.

What is Zenas Biopharma Inc's Revenue forecast?
Projected CAGR
130%

For the last 1 year the compound annual growth rate for Zenas Biopharma Inc's revenue is -90%. The projected CAGR for the next 4 years is 130%.

Back to Top